Copper-Based Targeted Nanocatalytic Therapeutics for Non-Small CellLung Cancer
ABSTRACT Conventional treatments for non-small cell lung cancer(NSCLC) sufer from low remission rates, high drug resistance, and severeadverse efects.
KRAS–LKB1 (KL) co-mutant non-small cell lung cancer (NSCLC) is characterized by an immunologically “cold” tumor immune microenvironment (TIME), and resultantly exhibits intrinsic resistance to immune checkpoint inhibitor (ICI) therapy.
Home
Phone
Message
Back to Top